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Abstract
Objectives
Compounds characterized by a peroxidic skeleton are an
interesting starting point for antischistosomal drug discovery.
Previously a series of 3-alkoxy-1,2-dioxolanes, which are
chemically stable cyclic peroxides, demonstrated significant in
1
vitro activity against Plasmodium falciparum. We aimed to
evaluate the potential of these compounds against Schistosoma
mansoni and elucidate the roles of iron and peroxidic groups in
activity.
Methods
Drugs were tested against juvenile and adult stages of S.
mansoni in vitro and in vivo. Selected structures were
assessed in vitro against schistosomes in the presence of
additional iron sources. In addition, drugs were tested in vitro
and in vivo against Echinostoma caproni, a non-blood-feeding
intestinal fluke. Finally, the activity of non-peroxidic analogues
was evaluated.
Results
Three dioxolanes displayed IC50s ≤20.1 μM against adult
schistosomes and values as low as 4.2 μM against newly
transformed schistosomula. Nonetheless, only moderate, non-
significant worm burden reductions were observed after
treatment of mice harbouring adult infections. Drugs lacked
activity against juvenile schistosomes in vivo. Two selected
dioxolanes showed in vitro activity against E. caproni down to
concentrations of 5 mg/L, but none of the compounds revealed
in vivo activity. All tested non-peroxidic analogues lacked activity
in vitro against both parasites.
Conclusions
Selected dioxolanes presented interesting in vitro activity, but
low in vivo activities have to be overcome to identify a lead
candidate. Although the inactivity of non-peroxidic analogues
underlines the necessity of a peroxide functional group,
incubation of adult schistosomes with additional iron sources did
not alter activity, supporting an iron-independent mode of
2
activation.
Introduction
Schistosomiasis is a neglected tropical disease caused by trematode
flatworms of the genus Schistosoma. Five species of schistosomes infect
humans, with Schistosoma haematobium, Schistosoma japonicum and
Schistosoma mansoni being responsible for the main burden of
schistosomiasis.1 Approximately 200 million people are affected by
schistosomiasis, mainly in sub-Saharan Africa.2 Praziquantel is currently
the gold standard for the treatment of schistosome infections. Because of the
threat of drug resistance and the limitations in the activity profile of
praziquantel (the drug lacks activity against the juvenile schistosome
stages), identification of potential drug candidates has a high priority.
The antischistosomal potential of the antimalarials artemisinin and its
semisynthetic derivatives artesunate and artemether has been studied
thoroughly in the past three decades, in in vitro and in vivo studies, and in
clinical trials.3–5 Given the promising activity profile of the artemisinins,
with particularly high activities observed against juvenile schistosomes,
different groups of fully synthetic peroxides have been studied in vivo and
in vitro in recent years.6,7 For example, the synthetic trioxolane OZ418 was
recently introduced as a promising drug candidate showing high worm
burden reductions (WBRs) of 80% and 86% against S. mansoni and S.
haematobium, respectively.8
The high antimalarial activity of 1,2,4-trioxolanes triggered investigations
with 1,2-dioxolanes, which are structurally analogous five-membered ring
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peroxides offering enhanced chemical stability. However, the dioxolanes
proved much less active than the corresponding 1,2,4-trioxolanes against
Plasmodium falciparum in vitro and Plasmodium berghei in vivo.9 This
reduction in activity has been attributed to a decreased tendency for scission
of the alkoxy radicals derived from Fe(II) activation of the 1,2-dioxolane
peroxide;10 β-scission to generate carbon radicals is considered important
for the activity of peroxide antimalarials.11 3-Alkoxy-1,2-dioxolanes, which
undergo activation by Fe(II) to generate oxygen-substituted alkoxy radicals
closely related to the intermediates derived from trioxolanes, generate
products indicative of efficient β-scission and have been shown to have
promising antimalarial efficacy.10
To our knowledge the antischistosomal activity of the 3-alkoxy-1,2-
dioxolanes has not been studied to date. In the present work 18 selected 3-
alkoxy-1,2-dioxolanes were tested on S. mansoni in vitro and active
candidates were followed up in vivo. To investigate whether the peroxide
pharmacophore is an essential requirement for antischistosomal activity,
non-peroxidic analogues of active compounds were synthesized and their
antischistosomal potential was determined. In addition, the relationship
between the parasite's haemoglobin consumption and the antischistosomal
activity of compounds was studied in vitro by testing active compounds on
the non-blood-feeding foodborne trematode Echinostoma caproni and
evaluating the in vitro activity of active compounds under different
incubation conditions, in media containing haemin, haemoglobin or red
blood cells.
Materials and methods
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Drugs
The 18 3-alkoxy-1,2-dioxolane substrates illustrated in Table 1 were
prepared based upon methods described by Schiaffo et al.10 Two non-
peroxidic analogues were prepared as illustrated in Figure S1 (available as
Supplementary data at JAC Online).
See full table
Table 1. Chemical structures of investigated 3-
alkoxy-1,2-dioxolanes and determined IC50 values
(mean of three experiments) against newly
transformed schistosomula (NTS) and adult S.
mansoni 72 h post-compound exposure; r represents
goodness of fit (conformity with r ≥ 0.85)
Animals and parasites
Animal studies were conducted following Swiss regulations on animal
welfare at the Swiss Tropical and Public Health Institute (Basel,
Switzerland, permission no. 2070). Three-week-old (weight ∼14 g) female
NMRI mice were purchased from Charles River (Sulzfeld, Germany) or
Harlan Laboratories (Horst, The Netherlands). Before starting experiments,
animals were allowed to adapt for 1 week under controlled conditions
(temperature ∼22°C; humidity ∼50%; 12 h light and 12 h dark cycle; free
access to rodent diet and water). Infection of mice with S. mansoni
(Liberian strain) was performed subcutaneously by injection of 80–100
cercariae. Cercariae were harvested from infected intermediate host snails
(Biomphalaria glabrata) by exposure to light for 3 h, following the standard
procedures of our laboratory. For in vitro and in vivo studies with E.
caproni, mice were infected intragastrically with 30 metacercariae harvested
from infected B. glabrata snails.
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In vitro screening
Preparation of NTS and adult schistosomes
NTS were obtained by mechanical transformation of S. mansoni
cercariae.12,13 Cercariae were collected as described above. The
schistosomula suspension was adjusted to a concentration of 100 NTS per
50 μL with Medium 199 (Invitrogen, Carlsbad, CA, USA) supplemented
with 5% heat-inactivated fetal calf serum (iFCS), 100 U/mL penicillin and
100 mg/L streptomycin (Invitrogen). To ensure completed conversion from
cercariae to NTS, suspensions were incubated at 37°C in an atmosphere of
5% CO2 in ambient air for a minimum of 12–24 h until use.14
Adult flukes were harvested from hepatic portal veins and mesenteric veins
of infected NMRI mice (7–8 weeks post-infection) following standard
procedures.6 Schistosomes were placed in RPMI 1640 culture medium
supplemented with 5% iFCS, 100 U/mL penicillin and 100 mg/L
streptomycin at 37°C in an atmosphere of 5% CO2 until use.
Preparation of adult E. caproni
Infected mice were killed 2 weeks post-infection. Trematodes were
harvested from the excised small intestine and placed in RPMI medium
supplemented with 100 U/mL penicillin, 100 mg/L streptomycin and 1% α-
D-glucose (Sigma Aldrich, St Louis, MO, USA). Flukes were maintained at
37°C in an atmosphere of 5% CO2 in ambient air until use.
Drug susceptibility assays with NTS
Drug dilution series with concentrations ranging from 0.37 to 90 mg/L
(0.37, 1.1, 3.3, 10, 30, 90 mg/L) were prepared in 96-well flat-bottom plates
(BD Falcon, USA) using supplemented medium (with iFCS and antibiotics).
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Prepared NTS suspension containing 100 NTS per 50 μL was added to each
well to yield a total volume of 250 μL per well. The highest DMSO
concentration (1.1%) used, diluted in Medium 199, served as control. Plates
were incubated at 37°C in an atmosphere of 5% CO2. NTS were evaluated
by microscopic readout (Carl Zeiss, Germany, magnification ×80) with
regard to death, changes in motility, viability and morphological alterations
24, 48 and 72 h post-drug exposure. As described previously, drug effects
were evaluated using a viability scale.12,13 Parasite fitness, morphology and
motility were classified with scores ranging from 3 (normal activity, no
morphological changes) to 0 (all worms dead). Duplicate examinations were
performed for each concentration and experiments were repeated at least
three times. IC50 values of the investigated drugs based on motility scale
values obtained at the 72 h timepoint were determined using CompuSyn
software (Version 3.0.1, 2007; ComboSyn, Inc.).
Drug susceptibility assay with adult schistosomes
In vitro screening on adult flukes was performed in 24-well flat-bottom
plates (BD Falcon, USA). Supplemented RPMI 1640 medium (with iFCS
and antibiotics) and drug stock solutions (10 mg/mL) were used to obtain
final test concentrations of 1–90 mg/mL (1.1, 3.3, 10, 30, 90 mg/L) in wells
with a final volume of 1.4 mL. Finally, three schistosomes of both sexes
were added to each well. The highest concentration of DMSO (0.3%) in
medium served as control. Twenty-four, 48 and 72 h post-drug exposure,
phenotypes were monitored using the motility scale described by Ramirez et
al.15 and an inverse microscope (Carl Zeiss, Germany, magnification ×80).
Experiments were performed three times. IC50 values were calculated with
CompuSyn software as described above for NTS (Version 3.0.1, 2007;
ComboSyn, Inc.).
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Drug susceptibility assay of adult S. mansoni in the presence of haemin,
haemoglobin or red blood cells
Lead candidates were incubated as described above, but using different
RPMI culture medium conditions. A haemin solution (1.5 mM) was
prepared as follows: 50 mg haemin chloride (Fluka Analytical, The
Netherlands) was dissolved in 10 mL of 0.1 M NaOH, 0.5 mL of 1 M HCl
and 39.5 mL of PBS (pH = 7.4). The haemoglobin solution (0.23 mM) was
prepared using 750 mg haemoglobin from bovine blood (Sigma Aldrich,
USA) dissolved in the same amounts of NaOH, HCl and PBS as used above.
Finally, supplemented RPMI media were prepared by adding 8% haemin
solution, 10% haemoglobin solution or 2% red blood cells from red blood
cell concentrate (blood group A Rhesus positive) to final concentrations in
well plates of 120 μM for haemin, 23 μM for haemoglobin or 2% for red
blood cells. At timepoints 24, 48 and 72 h post-exposure, phenotypes were
monitored using the motility scale as described above using an inverse
microscope (Carl Zeiss, Germany, magnification ×80) and data were
compared between various incubation conditions.15
Isothermal microcalorimetry (IMC) drug assay with adult S. mansoni
Two non-peroxidic analogues (compounds 19, 20) and one selected
dioxolane (compound 16) were further characterized using IMC as
described by Manneck et al.16 Briefly, heat production and motility (derived
from noise amplitudes) of schistosomes were measured using a 48-channel
microcalorimeter (model TAM 48; TA Instruments, New Castle, DE, USA)
over a period of 5 days. Samples were prepared in glass ampoules with 2900
μL of medium (supplemented RPMI 1640) containing four adult worms.
Pre-warmed (37°C) ampoules were placed in channels and equilibration was
performed for 12 h until a stable signal was observed. Drug suspensions
8
(concentration of 900 mg/L) in supplemented medium (volume 100 μL)
were injected, using 1 mL syringes (BD Plastipak, Becton Dickinson S.A.,
Madrid, Spain), to reach the final concentration of 30 mg/L per ampoule.
Ampoules with dead worms served as the negative control and ampoules
with worms treated with the highest concentration of DMSO (0.3%) served
as the positive control. Heat flow was recorded as 1 data point per 1 min
over at least 120 h. Tests at each concentration were performed three times.
Drug susceptibility assay with adult E. caproni
Assays were prepared in 24-well flat-bottom plates (Costar). Drug dilutions
were prepared with drug stock solutions and supplemented RPMI medium
(with antibiotics and glucose) to obtain final drug concentrations of 5–100
mg/L (5, 10, 50, 100 mg/L) in a total volume of 2 mL per well. Six to nine
trematodes were used (one or two worms per well) for each experimental
group. The highest concentration of DMSO (1%) served as control. Plates
were incubated at 37°C in an atmosphere of 5% CO2. Twenty-four, 48 and
72 h post-drug exposure, phenotypes and mortality of worms were
monitored as described elsewhere.12
In vivo screening
Studies with S. mansoni
Groups of four infected NMRI mice characterized by a patent schistosome
infection (49 days post-infection) or a juvenile Schistosoma infection (21
days post-infection) were treated orally with the test drug using single oral
doses of 400 mg compound per kg body weight. Seven to nine untreated
mice served as controls. Animals harbouring an adult Schistosoma infection
were killed by the CO2 method 14 days post-treatment, and mice treated at
the juvenile infection stage were sacrificed 4 weeks post-treatment. Mice
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were then dissected and worms sexed and counted.6 Worm burdens of
treated mice were compared with those of untreated animals and reductions
of worm burden calculated.
Studies with E. caproni
Four NMRI mice were treated intragastrically with 400 mg/kg of test
compounds 2 weeks post-infection with E. caproni. Four mice were left
untreated and served as controls. One week post-treatment, mice were
euthanized with CO2. At necropsy, the intestines were removed from the
pylorus to the ileocaecal valve, placed in a Petri dish and opened
longitudinally. All E. caproni worms were removed and counted.
Statistics
Parasite motility of treated and untreated NTS and adult trematodes was
calculated as mean (±SD) using Microsoft Excel software. Motility data
obtained from experiments with various media containing iron sources were
compared using the Mann–Whitney test (considered significant at P ≤ 0.05).
IC50 values were determined using the CompuSyn software (Version 3.0.1,
2007; ComboSyn, Inc.). For the comparison of IC50 values we used the
Kruskal–Wallis test (considered significant at P ≤ 0.05). The Kruskal–Wallis
test was also used for in vivo studies, comparing the medians of the
responses between the treatment and control groups. A difference in median
was considered to be significant at a significance level of 5% (StatsDirect
statistical software, version 2.7.2.; StatsDirect Ltd, UK). Noise amplitudes
and heat flows observed in calorimetric in vitro assays with adult S.
mansoni were analysed using R software and Microsoft Excel. As described
by Manneck et al.,17 noise amplitude values follow an exponential decay.
Endpoints of worm motility were determined by the intersection of the
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sample amplitude curve with the background signal noise of dead worms.
Results
In vitro screening against S. mansoni
In a first step, 14 3-alkoxy-1,2-dioxolanes were studied against adult S.
mansoni in vitro. Three of the compounds (1, 2 and 3) demonstrated good
antischistosomal activity with IC50s of 11.9, 12.4 and 20.1 μM,
respectively, against adult flukes. The remaining 11 substances revealed
only minor activity (IC50s between 49.2 and 283.3 μM) or lacked activity
(compound 14). Good activities were observed against the juvenile
schistosome stage (NTS) for compounds 2 (IC50 7.5 μM) and 3 (IC50 4.2
μM). Moderate activity was detected for compounds 1 (IC50 31.1 μM), 5
(IC50 17.0 μM) and 6 (IC50 35.9 μM) against NTS. Finally, only minor
activity was recorded for the remaining nine compounds against NTS (IC50
42.6–102.5 μM). In vitro findings are summarized in Table 1. For
comparison, activities of standard antischistosomal drugs, praziquantel and
artesunate, are also shown in Table 1.
Influence of haemin, haemoglobin or red blood cells on in vitro
antischistosomal activity
Incubation of adult schistosomes with various concentrations (1.1, 3.3, 10,
30 mg/L) of the three active alkoxydioxolanes (1–3) in supplemented media
containing haemin, haemoglobin or red blood cells showed no significant
differences in activity. The motilities recorded 72 h post-exposure of S.
mansoni with compound 1 at different concentrations did not vary among
the different media tested (Figure 1). Slightly higher, though not significant
(P > 0.05) activities were detected for compounds 2 and 3 when incubated in
11
the presence of haemin or haemoglobin. In the presence of these media all
worms had died 72 h post-exposure to the tested compounds at a
concentration of 10 mg/L and 30 mg/L.
View larger version
Figure 1. Motility of adult schistosomes 72 h post-treatment
with various concentrations (1.1, 3.3, 10 and 30 mg/L) of
compounds 1, 2 or 3 in four different incubation settings. (a)
Standard incubation with supplemented RPMI. (b) Addition of 2% red blood cells from
red blood cell concentrate. (c) Addition of 120 μM haemin. (d) Addition of 23 μM
haemoglobin.
In vivo activity of selected alkoxydioxolanes against S. mansoni
The three lead structures 1–3 identified by prior in vitro screening, were
tested in a juvenile as well as an adult S. mansoni infection mouse model
(Table 2). All studied alkoxydioxolanes lacked in vivo activity against
juvenile S. mansoni (Table 2; WBRs 0%–4%). However, moderate, non-
significant activities were observed with compounds 1 and 2 against adult S.
mansoni with WBRs of 42.5% and 37.0%, respectively. Compound 3 showed
only low activity against adult S. mansoni in vivo with a WBR of 15.1%.
Dead worms were detected in mouse livers after treatment of adult
infections with compounds 1, 2 and 3. The presence of a patent schistosoma
infection in treated animals was confirmed by observing granulous tissue
and Schistosoma eggs within all livers.
12
See full table
Table 2. In vivo activity following a single oral
dose of 400 mg/kg of selected 3-alkoxy-1,2-
dioxolanes in mice harbouring juvenile or adult S.
mansoni
In vitro and in vivo activity of modified lead dioxolanes against S.
mansoni
Given the low in vivo activity of the three test drugs, we were motivated to
investigate four additional chemically related alkoxydioxolanes in vitro
against NTS and adult schistosomes, followed by in vivo studies on a patent
S. mansoni infection. All four compounds (15–18) showed very high
activities against NTS, represented by low IC50 values (2.7–4.8 μM)
(summarized in Table 1). However, the four drugs revealed only low
activities against adult schistosomes in vitro, with IC50s between 49.4 and
109.3 μM. Moderate, but non-significant, in vivo WBRs of 32.0% and 21.3%
were achieved with compounds 15 and 17, respectively. Low activities with
WBRs of 12.0% and 16.4% were observed with compounds 16 and 18,
respectively (summarized in Table 3).
See full table
Table 3. In vivo activity following a single oral
dose of 400 mg/kg of selected 3-alkoxy-1,2-
dioxolanes in mice harbouring adult S. mansoni
In vitro and in vivo effect against E. caproni
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Lead structures 1–3 as well as the four related structures (15–18) were
tested in vitro on freshly harvested E. caproni. Data are summarized in
Table 4. Six of seven compounds (1, 3, 15–18) showed 100% worm
mortality 24 h post-drug exposure at a concentration of 50 mg/L. Two of the
compounds (16 and 17) killed all worms 24 h post-incubation at a 5-fold
lower concentration of 10 mg/L. Incubation of adult E. caproni with three
spirocyclohexyl compounds (3, 16 and 17) at 5 mg/L for 72 h resulted in
death of all worms. Compounds 15–17 were followed up in vivo. Treatment
of E. caproni-infected mice with a single oral dose of 400 mg/kg of
compound 15 resulted in a low WBR of 17.4%. Compounds 16 and 17
lacked in vivo activity (Table 5).
See full table
Table 4. In vitro mortality of E. caproni worms at
timepoints 24, 48 and 72 h post-drug treatment with
selected compounds
See full table
Table 5. In vivo activity following a single oral
dose of 400 mg/kg of selected 3-alkoxy-1,2-
dioxolanes against E. caproni in mice
In vitro activity of non-peroxidic analogues
To elucidate the role and necessity of the peroxide core of the
alkoxydioxolanes for trematocidal activity we tested the in vitro activity of
two alkoxy-substituted tetrahydrofurans (19, 20) prepared as non-peroxidic
14
analogues of the alkoxydioxolanes. Both derivatives lacked activity at
concentrations of 30 and 90 mg/L against S. mansoni. Also, E. caproni was
not affected at 50 and 100 mg/L. No effect against adult S. mansoni could be
observed by microscopic examination 72 h post-treatment as well as by
IMC 6 days after treatment. According to IMC, no loss of motility was
detected for either non-peroxidic compound over an incubation period of 6
days (concentration 30 mg/L). For comparison, treatment of adult S.
mansoni with 30 mg/L of the peroxidic analogue of compound 19
(compound 16) revealed a reduction in heat flow and complete loss of
motility was detected 90 h post-exposure (Figure 2).
View larger version
Figure 2. Course of heat flow (μW) over time (h) after
treatment of schistosomes with compound 19 (non-
peroxidic) or compound 16 (peroxidic). Control
schistosomes correspond to schistosomes treated with DMSO at the same
concentration as used for drugs (0.3%). Amplitudes of curves represent the motility of
schistosomes.
Discussion
The antischistosomal activity of semisynthetic artemisinins, frequently used
in malaria treatment, synthetic trioxolanes and hybrid molecules of quinines
and trioxanes has been well described.7,8 Compounds characterized by a
peroxidic skeleton are therefore an interesting starting point for
antischistosomal drug discovery. Hence, we were interested in elucidating
the antischistosomal potential of recently introduced alkoxydioxolanes as
well as their structural needs for activity against schistosomes.10
Three of 14 compounds tested (compounds 1–3) showed promising in vitro
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activity against adult S. mansoni flukes. Two of these compounds (2 and 3)
also revealed very good efficacy against the juvenile stage (NTS) in vitro.
The antischistosomal in vitro activity seems to be enhanced by the presence
of a bulky substituent at C3, since the three lead compounds all feature a
large alkoxide side chain at C3. The remaining non-active 11 compounds do
not display this feature. This finding is in accordance with observations
reported by Schiaffo et al.10 on the antimalarial structure–activity
relationship of similar compounds. These studies revealed that antimalarial
activity is enhanced by a spirocyclohexyl group at C5/C5′ and by the
presence of a steric bulk at C3. However, for antischistosomal activity it
does not seem to matter whether substitution at C5/C5′ is a dimethyl
(compound 2) or spirocyclohexyl (compound 3) group. On the other hand, it
is interesting to note that, with regard to E. caproni, the three most active
compounds (3, 16 and 17) all display spirocyclohexyl units.
In our in vivo studies we observed only moderate, non-significant activities
of alkoxydioxolanes in S. mansoni-infected NMRI mice. Compound 1
showed the highest in vivo activity against adult S. mansoni, achieving a
total WBR of 42.5% and a female WBR of 47.1%. In contrast to results
reported for artemisinins, surprisingly low WBRs were observed against
juvenile S. mansoni harboured in mice.18 A recent study conducted with a
library of dioxolanes revealed that the majority of the compounds tested
against rat and human microsomes were metabolized rapidly. It was
concluded that significant optimization of the groups attached to the
dioxolane core is needed before a viable candidate for drug development
could be identified.19 Hence, it is likely that the alkoxydioxolanes tested in
this study also exhibit bioavailability problems which can likely play a role
in limiting in vivo activities.
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In the present work we also studied the activity of alkoxydioxolanes in the
presence of various additional iron sources, since haemoglobin metabolism,
the potential target of these drugs, is a common feature of both Schistosoma
and Plasmodium spp.20 Earlier studies investigated the relationship between
Fe(II) reactivity, the efficiency of haem alkylation and antimalarial activity
for various peroxides in vitro. The authors stated that Fe(II) reactivity for
the tested peroxide heterocycles is a necessary, but insufficient, property of
antimalarial peroxides,21 and the alkoxydioxolanes have been shown to
undergo cleavage to alkoxy radicals in the presence of iron(II).10
Interestingly, we did not observe significant differences in susceptibility of
the tested agents in the different iron-source-containing media. This finding
is in contrast to the haemin-dependent antischistosomal in vitro effect of the
trioxolane OZ78 on S. mansoni and S. japonicum, whereas similar haemin-
independent activity was described for OZ209.6,22 Similarly, it was recently
shown that the antimalarial arylmethanol mefloquine, a drug class also
described to interfere with haemoglobin degradation in Plasmodium,
revealed a 57-fold lower IC50 in the presence of haemoglobin against adult
S. mansoni in vitro.23 Our results suggest that the alkoxydioxolanes possess
an iron-independent mechanism of action on schistosomes in vitro. This
discovery is supported by the observed high in vitro activities of three
compounds (3, 16 and 17) at concentrations as low as 5 mg/L against the
non-haematophagous intestinal fluke E. caproni.
Nonetheless, the results with the isosteric compounds that lack a peroxide
functional group underline the necessity of the peroxidic core for
trematocidal activity. Both compounds lacked in vitro activity against adult
S. mansoni and E. caproni. Similar results were recently demonstrated in
studies with the liver fluke Fasciola hepatica. While OZ78 has excellent in
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vitro and in vivo activity against F. hepatica, its non-peroxidic analogue
failed to show an effect against the fluke.24 The peroxidic feature seems
therefore to play a role in the iron-independent mode of action. The basis for
the iron-independent activity of the alkoxydioxolanes is unclear. These
molecules, like all peroxides, are oxidants, and in principle capable of
reaction with strongly nucleophilic or reducing agents. Alternatively, it is
possible that the alkoxydioxolanes undergo activation via acid-catalysed
ring opening of the peroxyacetal core to generate a more reactive 3-
hydroperoxyketone; a similar model has been proposed to account for the
antimalarial activity of artemisinin.25
In conclusion, we have demonstrated that a number of alkoxydioxolanes are
characterized by good in vitro antischistosomal activity and non-significant
in vivo effects on S. mansoni, with compound 1 being the most promising
candidate. Similarities, but also differences, exist between antimalarial and
antischistosomal activity of alkoxydioxolanes. The peroxidic bond is
essential to antischistosomal activity, but activation of the molecules seems
to be independent of iron. The low in vivo activity of this drug class, which
may result from limited bioavailability, represents a challenge that would
need to be overcome in order to identify an antischistosomal lead candidate.
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Table 1.
Chemical structures of investigated 3-alkoxy-1,2-dioxolanes and determined IC50 values
(mean of three experiments) against newly transformed schistosomula (NTS) and adult S.
mansoni 72 h post-compound exposure; r represents goodness of fit (conformity with r ≥ 
0.85)
Compound
IC50 (μM) for 
R1 R2 R3 R NTS
1 Me Me Me 31.1
2 Me Bu Me CH2CH2Ph 7.5
3 -(CH2)5- CH2CH2Ph CH2CH2Ph 4.2
4 Me Me CH2Ph Me 101.0
5 17.0
6 Me Me Me 5,6-epoxyhexyl 35.9
7 Me Me Me CH2CH2CN 89.2
8 -(CH2)5- Me CH(OH)CH2OH 90.9
23
9 Me Me Me (CH2)9CO2Me 89.7
10 Me Me Me CH2CH2CO2Me 76.0
11 Me Me Me CH2CH2OMe 69.2
12 Me Me Me CH2CH2 CH2OH 42.6
13 Me Me Me (CH2)4CO2Me 59.8
14 Me Me Me CH(OH)CH2OH 102.5
15 Me Me Me CH2CH2Ph 2.7
16 -(CH2)5- Me CH2CH2Ph 2.8
17 -(CH2)5- Me 4.1
18 Me Me Me 4.8
Praziquantel 2.2
Artesunate 5.0
aAs described by Keiser et al.26
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Figure 1.
Motility of adult schistosomes 72 h post-treatment with various concentrations (1.1,
3.3, 10 and 30 mg/L) of compounds 1, 2 or 3 in four different incubation settings. (a)
Standard incubation with supplemented RPMI. (b) Addition of 2% red blood cells
from red blood cell concentrate. (c) Addition of 120 μM haemin. (d) Addition of 23
μM haemoglobin.
[Back]
26
[Back]
Table 2.
In vivo activity following a single oral dose of 400 mg/kg of selected 3-alkoxy-1,2-
dioxolanes in mice harbouring juvenile or adult S. mansoni
Group
No. of mice
investigated
No. of
mice that
died
No. of
mice
cured
TWR
(%)
P
value
FWBR
(%)
P
value
Control 8 0 0 − − − −
Juvenile
infection
 1 4 0 0 0 0.73 0 0.86
 2 4 0 0 4.1 0.67 5.9 0.38
 3 4 0 0 0 0.87 0 0.44
Adult
infection
 1 4 0 0 42.5 0.27 47.1 0.23
 2 4 0 0 37.0 0.35 41.2 0.35
 3 4 0 0 15.1 0.86 17.7 0.73
TWR, total worm burden reduction; FWBR, female worm burden reduction.
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Table 3.
In vivo activity following a single oral dose of 400 mg/kg of selected 3-alkoxy-1,2-
dioxolanes in mice harbouring adult S. mansoni
Group
No. of mice
investigated
No. of mice
that died
No. of
mice cured
TWR
(%)
P
value
FWBR
(%)
P
value
Controla 7 0 0 − − − −
Controlb 9 0 0 − − − −
15a 4 1 0 32.0 0.1 37.8 0.1
16a 4 1 0 12.0 0.7 5.4 0.7
17a 4 1 0 21.3 0.4 35.1 0.3
18b 4 0 0 16.4 0.9 11.9 0.7
TWR, total worm burden reduction; FWBR, female worm burden reduction.
aVersus control.
bVersus control.
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Table 4.
In vitro mortality of E. caproni worms at timepoints 24, 48 and 72 h post-drug treatment
with selected compounds
Drug
Drug
concentration
(mg/L)
No. of worms
observed
Percentage of worms that died
after indicated time
0 h 24 h 48 h 72 h
Control − 20 0 0 0 0
1 100 8 0 100
50 8 0 100
10 7 0 43 100
5 8 0 25 75 88
2 100 6 0 100
50 6 0 0 100
10 6 0 17 67 100
5 7 0 0 29 57
3 100 6 0 100
50 7 0 100
10 7 0 57 100
29
5 9 0 22 100
15 100 6 0 100
50 6 0 100
10 7 0 86 100
5 8 0 0 38 75
16 100 6 0 100
50 6 0 100
10 7 0 100
5 6 0 50 67 100
17 100 6 0 100
50 7 0 100
10 6 0 100
5 7 0 0 100
18 100 6 0 100
50 7 0 100
10 6 0 67 83 100
5 6 0 0 17 33
[Back]
30
[Back]
Table 5.
In vivo activity following a single oral dose of 400 mg/kg of selected 3-alkoxy-1,2-
dioxolanes against E. caproni in mice
Group
No. of mice
investigated
No. of mice
cured
Worms
TWR
(%)
P
value
Control 4 0 23.0 (0) − −
15 4 0
19.0
(7.2)
17.4 0.2
16 4 0
27.8
(4.5)
0 0.2
17 4 0
23.0
(7.8)
0 0.5
TWR, total worm burden reduction.
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Figure 2.
Course of heat flow (μW) over time (h) after treatment of schistosomes with
compound 19 (non-peroxidic) or compound 16 (peroxidic). Control schistosomes
correspond to schistosomes treated with DMSO at the same concentration as used
for drugs (0.3%). Amplitudes of curves represent the motility of schistosomes.
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